A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Clazakizumab (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- 10 Jun 2021 Planned End Date changed from 1 Jun 2021 to 1 May 2022.
- 10 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 May 2022.
- 15 Feb 2021 Planned End Date changed from 1 Feb 2021 to 1 Jun 2021.